COMPANY PROFILE

Rational Vaccines

Explore full profile

The world’s first line of live-attenuated herpes simplex virus vaccines

Woburn, United StatesFounded 2015Biotech & Life Sciences

Valuation $25–50M Last recorded · 2018

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Rational Vaccines

Rational Vaccines is a pioneering biotech company focused on developing advanced vaccines to combat herpes simplex virus (HSV) infections and other infectious diseases. Operating in the infectious disease market, Rational Vaccines serves a global clientele, including healthcare providers, researchers, and patients affected by HSV-1 and HSV-2. The company leverages its proprietary vaccine technology to create live attenuated vaccines, which are designed to be safer and more effective than traditional methods. By focusing on precise design and scientific rigor, Rational Vaccines aims to address the unmet medical needs in the treatment and prevention of herpes and other infectious diseases. The business model revolves around research and development, clinical trials, and eventual commercialization of their vaccine products. Revenue is generated through partnerships, grants, and future sales of approved vaccines.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: Woburn, United States
Employees: 11
Open positions: None listed
Dealroom signal: 69.5/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Vaccines, Immune System, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

8 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
GRANTOther financing	Oct 2023	$2.8M	—	National Institutes of Health	↗
CONVERTIBLEOther financing	Mar 2022	$0	—	Globivest	—

Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Rational Vaccines website traffic

Latest recorded traffic for Rational Vaccines is 1.3K monthly website visits, up 2500% over the last three months. Rational Vaccines's team declined 8.3% over the past year.

Latest monthly visits1.3K 3-month web change+2500% 1-year team growth-8.3%

Monthly website visitsOct 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DEDesentumBiopharma company in Finland developing allergy vaccines that change the way the immune system reacts to allergens	Espoo, Finland	Operational	13	$53M	$79M
ETElicio TherapeuticsTransforming the lives of patients and their families by re-engineering the body’s immune response to cancer	Cambridge, United States	Operational
IMIMMUNETHEPBiotech start-up company that is developing broad coverage anti-bacterial immunotherapies	Cantanhede, Portugal	Operational
BIBioNTechDevelops personalized immunotherapies with a focus on cancer medicine	Mainz, Germany	Operational
IMImmuneedDeveloping a new generation of prostate cancer vaccines, based on activation of the body's own immune system	Uppsala kommun, Sweden	Acquired
SPSpyBiotechNovel vaccine platform using protein superglue technology	Oxford, United Kingdom	Operational
ATAmal TherapeuticsDeveloping and progressing therapeutic cancer vaccines	Geneva, Switzerland	Acquired
HPHookipa PharmaHookipa Pharma	Vienna, Austria	Operational